| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
156,320,000 |
| Market
Cap: |
6.65(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$20.26 - $43.27 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Cerevel Therapeutics Holdings is a clinical-stage biopharmaceutical company. Co.'s programs: Emraclidine is a positive allosteric modulator (PAM), that selectively targets the muscarinic acetylcholine 4 receptor subtype; Darigabat, which is a PAM that selectively targets the alpha-2/3/5 subunits of the GABAA receptor; Tavapadon, which is a selective dopamine D1/D5 receptor partial agonist that it is developing for the treatment of early- and late-stage Parkinson's disease; and CVL-871, which is a selective dopamine D1/D5 receptor partial agonist specifically designed to achieve a level of partial agonism.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
17,422,701 |
18,847,701 |
| Total Buy Value |
$0 |
$0 |
$397,510,553 |
$447,385,553 |
| Total People Bought |
0 |
0 |
6 |
6 |
| Total Buy Transactions |
0 |
0 |
6 |
7 |
| Total Shares Sold |
154,667 |
359,132 |
611,027 |
1,200,893 |
| Total Sell Value |
$6,418,967 |
$14,072,755 |
$21,003,717 |
$39,590,443 |
| Total People Sold |
2 |
8 |
8 |
10 |
| Total Sell Transactions |
5 |
21 |
27 |
48 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Gordon Christopher R |
Director |
– • • |
2023-10-16 |
4 |
B |
$22.81 |
$124,999,986 |
I/I |
5,480,052 |
65,679,781 |
2.25 |
77% |
|
| Koppel Adam |
Director |
– • • |
2023-10-16 |
4 |
B |
$22.81 |
$124,999,986 |
I/I |
5,480,052 |
65,679,781 |
2.25 |
77% |
|
| Bain Capital Partners Xii, Llc |
10% Owner |
– – • |
2023-10-16 |
4 |
B |
$22.81 |
$124,999,986 |
I/I |
5,480,052 |
65,679,781 |
1.5 |
77% |
|
| Edelman Joseph |
Director |
– • – |
2023-10-16 |
4 |
B |
$22.81 |
$19,999,990 |
I/I |
876,808 |
10,794,876 |
2.1 |
77% |
|
| Coles N Anthony |
|
– • – |
2023-09-07 |
4 |
AS |
$24.07 |
$1,203,415 |
D/D |
(50,000) |
2,704 |
|
76% |
|
| Coles N Anthony |
|
– • – |
2023-09-07 |
4 |
OE |
$3.50 |
$175,000 |
D/D |
50,000 |
52,704 |
|
- |
|
| Burgess Paul D. |
See Remarks |
• – – |
2023-08-04 |
4 |
B |
$22.93 |
$501,794 |
D/D |
21,880 |
21,880 |
0.01 |
83% |
|
| Renaud Ronald C Jr |
President & CEO |
• • – |
2023-08-03 |
4 |
B |
$23.96 |
$2,008,811 |
I/I |
83,857 |
83,857 |
0.01 |
73% |
|
| Coles N Anthony |
|
– • – |
2023-07-11 |
4 |
AS |
$30.03 |
$1,501,340 |
D/D |
(50,000) |
2,704 |
|
-20% |
|
| Coles N Anthony |
|
– • – |
2023-07-11 |
4 |
OE |
$3.50 |
$175,000 |
D/D |
50,000 |
52,704 |
|
- |
|
| Bain Capital Partners Xii, Llc |
10% Owner |
– – • |
2023-06-07 |
4 |
D |
$0.00 |
$0 |
I/I |
(432,627) |
60,199,729 |
|
- |
|
| Dekkers Marijn E |
Director |
– • – |
2023-06-07 |
4 |
A |
$0.00 |
$0 |
D/D |
3,282 |
31,822 |
|
- |
|
| Koppel Adam |
Director |
– • • |
2023-06-07 |
4 |
D |
$0.00 |
$0 |
I/I |
(432,627) |
60,199,729 |
|
- |
|
| Koppel Adam |
Director |
– • • |
2023-06-07 |
4 |
A |
$0.00 |
$0 |
D/D |
3,282 |
3,282 |
|
- |
|
| Patrick Deval L |
Director |
– • – |
2023-06-07 |
4 |
A |
$0.00 |
$0 |
D/D |
3,282 |
3,282 |
|
- |
|
| Riedel Norbert G |
Director |
– • – |
2023-06-07 |
4 |
A |
$0.00 |
$0 |
D/D |
3,282 |
46,092 |
|
- |
|
| Giordano Douglas E. |
Director |
– • – |
2023-06-07 |
4 |
A |
$0.00 |
$0 |
D/D |
3,282 |
3,282 |
|
- |
|
| Mckernan Ruth |
Director |
– • – |
2023-06-07 |
4 |
A |
$0.00 |
$0 |
D/D |
3,282 |
3,282 |
|
- |
|
| Gordon Christopher R |
Director |
– • • |
2023-06-07 |
4 |
D |
$0.00 |
$0 |
I/I |
(432,627) |
60,199,729 |
|
- |
|
| Gordon Christopher R |
Director |
– • • |
2023-06-07 |
4 |
A |
$0.00 |
$0 |
D/D |
3,282 |
3,282 |
|
- |
|
| Greene Gabrielle E |
Director |
– • – |
2023-06-07 |
4 |
A |
$0.00 |
$0 |
D/D |
3,282 |
47,853 |
|
- |
|
| Bodenrader Mark |
See Remarks |
• – – |
2023-06-02 |
4 |
AS |
$32.95 |
$62,440 |
D/D |
(1,895) |
5,522 |
|
-32% |
|
| Bodenrader Mark |
See Remarks |
• – – |
2023-06-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,733 |
7,417 |
|
- |
|
| Coles N Anthony |
CEO and Chairperson |
• • – |
2023-06-01 |
4 |
AS |
$32.60 |
$1,630,070 |
D/D |
(50,000) |
2,704 |
|
-30% |
|
| Coles N Anthony |
CEO and Chairperson |
• • – |
2023-06-01 |
4 |
OE |
$3.50 |
$175,000 |
D/D |
50,000 |
52,704 |
|
- |
|
181 Records found
|
|
Page 3 of 8 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.04 (0.09%) 
